Jubilant Ingrevia
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Jubilant Ingrevia is poised for significant growth, driven by strong pricing in its Nutrition and Health Solutions (NHS) and Chemical Intermediates (CI) segments, alongside volume growth in Specialty Chemicals. Management's guidance for FY27 EBITDA of INR 7.5-8.0 billion reflects confidence in these segments, bolstered by a robust pipeline in the Contract Development and Manufacturing Organization (CDMO) space. The commissioning of a new multi-purpose plant by year-end is expected to enhance production capabilities, supporting revenue growth. However, potential risks include pricing pressures from commoditized products and limited visibility on new orders, particularly in the agrochemical CDMO segment. Vista's financial outlook anticipates accelerating revenue growth and improving margins, aligning with management's positive projections. The favorable macro environment in India, characterized by strong manufacturing activity and contained inflation, further supports this outlook. Over the next 12-24 months, key opportunities include the successful ramp-up of CDMO contracts and strategic capacity expansions, while watchpoints include execution risks and competitive pressures from Chinese suppliers
Why We Like This Stock
- Strong pricing in Nutrition and Health Solutions and Chemical Intermediates segments supports revenue growth
- The commissioning of a new multi-purpose plant is expected to enhance production capabilities
- Management's guidance for FY27 EBITDA reflects confidence in achieving significant growth
Things To Watch Out For
- Pricing pressures in commoditized products may impact margins
- Limited visibility on new orders in the agrochemical CDMO segment poses execution risks
- Competitive pressures from Chinese suppliers could challenge pricing power
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 4,136 | 4,178 | 4,388 | 5,002 | 5,529 |
| Profit Before Tax (Cr.) | 274 | 344 | 383 | 530 | 563 |
| PBT Margin | 6.6% | 8.2% | 872.8% | 10.6% | 10.2% |
| Net Profit (Cr.) | 162 | 251 | 296 | 409 | 434 |
| Earnings Per Share | 10.3 | 15.9 | 18.7 | 25.9 | 27.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Anand Rathi | ▲ Buy | 980 | 24-Jul-2026 |
| Axis Securities | ▲ Buy | 800 | 26-May-2026 |
| Choice Equity | ▲ Buy | 975 | 27-May-2026 |
| Kotak Securities | ▲ Buy | 940 | 01-Jul-2026 |
| Nuvama | ▲ Buy | 994 | 31-May-2026 |
| Prabhudas Liladhar | ► Hold | 711 | 24-Jul-2026 |
Company Overview
Show Company Profile
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.